SCHEMBL3961593

SCHEMBL3961593

CNC(=O)c1cccc2sc(-c3nc(Cl)ncc3C)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 4/20 0.40
JAK1 P23458 4/20 0.40
TYK2 P29597 4/20 0.40
JAK3 P52333 4/20 0.40
PLK1 P53350 1/20 0.39
MTNR1A P48039 1/20 0.36
SMN1; SMN2 Q16637 4/20 0.35
NPC1 O15118 4/20 0.35
RAB9A P51151 4/20 0.35
KMT2A Q03164 4/20 0.35
MEN1 O00255 3/20 0.35
MAPT P10636 3/20 0.35
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
POLB P06746 2/20 0.35
HPGD P15428 1/20 0.35
MAPK1 P28482 1/20 0.35
RECQL P46063 1/20 0.35
AR P10275 1/20 0.35
JUN P05412 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3966800 0.90 JAK2 (0.41) JAK2JAK1TYK2JAK3PLK1
SCHEMBL3965410 0.88 BTK (0.41) JAK2JAK1TYK2JAK3PLK1
SCHEMBL3970415 0.88 PDK1 (0.38) SMN1; SMN2NPC1RAB9AKMT2AMEN1
SCHEMBL3965483 0.87 RAB9A (0.42) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL3961533 0.80 CA2 (0.37) KDM4EPDK1PDK2PDK3PDK4
SCHEMBL3968816 0.78 HDAC6 (0.43) PLK1SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL3968825 0.77 BTK (0.39) NPC1RAB9AKMT2AMEN1MAPT
SCHEMBL3961637 0.76 BTK (0.39) SMN1; SMN2KMT2AMEN1KDM4EALDH1A1
SCHEMBL3964096 0.76 P2RX7 (0.44) SMN1; SMN2NPC1RAB9AKMT2AMEN1
SCHEMBL3964461 0.76 ICAM1 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1989200-B1 [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES LILLY CO ELI (US) 2009-07-29 EP disclosed
US-7547691-B2 [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases ELI LILLY AND COMPANY (US) 2009-06-16 US disclosed
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases ELI LILLY AND COMPANY 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases NFKBIA, IKBKB, IKBKG JAK2 67/4885JAK1 37/4885TYK2 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.